How LiquidMammo™ Works
LiquidMammo™ is a supplemental, non‑invasive blood‑based test that analyzes cancer‑associated microRNA signatures to support breast‑cancer screening — especially in dense‑breast populations.
LiquidMammo is being developed as a CLIA Laboratory Developed Test (LDT). It is not yet FDA‑cleared or FDA‑approved.
The process
1 — Ordered by clinician
The test is ordered through a clinician, like routine laboratory assays. A standard blood draw is all that is required.
2 — Plasma processing
Blood is collected, stabilized, and processed under validated SOPs to preserve circulating microRNAs.
3 — microRNA panel analysis
A proprietary multi‑marker panel quantifies dysregulation patterns associated with tumor biology.
4 — Classification & interpretation
Machine‑learning models integrate the signal with reference distributions and density‑aware context.
5 — Clinician‑ready report
The final report includes result category, contextual notes, and follow‑up recommendations.
Why microRNAs?
microRNAs regulate gene expression and are central to proliferation, immune signaling, and oncogenic stress responses. They remain stable in blood and can show dysregulation early in tumor development — often before structural changes appear on imaging.
Addressing dense‑breast limitations
- Mammography sensitivity may fall to ~61% in extremely dense tissue.
- Dense tissue can mask small or early‑stage lesions.
- Interval cancers occur more frequently in dense‑breast populations.
- A biological signal provides density‑independent consistency.
The role of LiquidMammo in screening pathways
LiquidMammo is a supplemental tool intended to strengthen screening workflows by adding a molecular layer that complements imaging.
- Clarifying equivocal imaging results
- Supporting decisions in dense‑breast patients
- Providing information for patients who defer mammography
- Enhancing confidence between screening intervals